Skip to main content
. 2023 Mar 28;16:29–43. doi: 10.2147/CEG.S340929

Table 1.

Meta-Analyses on Mesalazine Use in SUDD

Study Population Control Group Outcome
Khan, 201884 SUDD after at least one episode of acute uncomplicated diverticulitis. (PD-SUDD) Placebo Recurrence:

  • Overall: No difference (OR 1.2, 95% CI 0.96–1.5), I:2 9%

  • Subgroup analysis:


- Mesalazine dose ≤ 2g/day: No difference
(Five RCTs, OR 1.1, 95% CI 0.7–1.5), I2=27%.
- Mesalazine dose > 2g/day: higher recurrence with Mesalazine
(Four RCTs, OR 1.28, 95% CI 1.02–1.62), I2=0%
Iannone, 201885 SUDD and acute uncomplicated diverticulitis.
Excluded patients with acute complicated diverticulitis.		 Probiotics, Rifaximin, placebo, no treatment, or both probiotic and placebo Achievement of remission:

  • SUDD: (One RCT, 123 patients, OR 1.04; 95% CI 0.8–1.34)

  • Acute uncomplicated diverticulitis: Mesalazine may achieve remission


(One RCT, 81 patients, OR 2.67; 95% CI 1.05–6.79),
Disease recurrence:

  • SUDD: Mesalazine may decrease recurrence.

  • (Two RCTs, 216 patients, OR 0.52; 95% CI 0.28–0.97),

  • Acute uncomplicated diverticulitis:

  • (Seven RCTs, 2196 patients, OR 0.9; 95% CI 0.61–1.33)
Picchio, 201886 SUDD Placebo Symptom relief (achievement of remission):
 (Three RCTs, OR 0.4, 95% CI 0.24–0.75, I2=65%)
Diverticulitis occurrence:
 (Two RCTs, OR 0.35; 95% CI 0.17–0.70, I2=38%)

Abbreviations: SUDD, Symptomatic Uncomplicated Diverticular Disease; RCT, Randomized Controlled Trial; OR, Odd Ratio; CI, Confidence Interval.